Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

Oncogene volume 18, pages 2335–2341 (1999)Cite this article

Abstract

Experimental evidence from several sources has identified a link between mismatch repair deficiency and cytotoxic drug resistance. Selection for cisplatin resistance in the human ovarian cancer cell line A2780, results in loss of expression of the mismatch repair protein hMLH1 in most (90%) of the resultant cisplatin-resistant cell lines. Here we demonstrate that the cisplatin sensitive parental cell line displays methylation of the promoter of only one hMLH1 allele, but that the resistant cell lines all exhibit hyper-methylation of the promoters of both hMLH1 alleles. Full methylation of all sites tested was found to be invariably associated with loss of hMLH1 expression, whereas a partial increase in methylation appears compatible with either loss or maintenance of expression. In addition treatment of two of the resistant cell lines with 5-azacytidine, a known inhibitor of methylation, results in re-expression of hMLH1. Clonogenic assays demonstrate that the 5-azacytidine treated cells show increased sensitivity to cisplatin. Furthermore, 12.5% (3/24) of ovarian tumours show hypermethylation of the hMLH1 promoter. Expression of hMLH1 is absent in the tumours that are hypermethylated, while all the unmethylated tumours still express the protein. This analysis suggests that methylation of the hMLH1 promoter may be a common mechanism for loss of hMLH1 expression, and possibly for cisplatin-resistance, in ovarian cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Aaltonen LA, Peltomaki P, Leach PS, Sistonen P, Pylkkanen L, Maklin J, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B and de la Chapelle A. . 1993 Science 260: 812–815.

  • Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB. . 1996 Cancer Res. 56: 3087–3090.

  • Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J and Lindblom A. . 1994 Nature 368: 258–261.

  • Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG and Anthoney DA. . 1997 Oncogene 15: 45–52.

  • Eshleman JR and Markowitz SD. . 1995 Curr. Opin. Oncol. 7: 83–89.

  • Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD and Howell SB. . 1996 Cancer Res. 56: 4881–4886.

  • Fink D, Nebel S, Aebi S, Nehme A and Howell SB. . 1997 Int. J Oncol. 11: 539–542.

  • Fink D, Aebi S and Howell SB. . 1998 Clin. Cancer Res. 4: 1–6.

  • Frost P, Abbruzzese JL, Hunt B, Lee D and Ellis M. . 1990 Cancer Res. 50: 4572–4577.

  • Fujita M, Enomoto T, Yoshino K, Nomura T, Buzard GS and Inoue M. . 1995 Int. J. Cancer 64: 361–366.

  • Hatta Y, Wada M, Takeuchi S, Tasaka T, Lee E, Lee YY, Kim BK, Bang Y, Lee S, Yamada Y, Tomonaga M, Wilczynski SP, Said JW and Koeffler HP. . 1997 Int.J. Oncol. 11: 465–469.

  • Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JJ, Markowitz S, Willson JKV, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA and Baylin SB. . 1998 Proc. Natl. Acad. Sci. USA 95: 6870–6875.

  • Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM and Kolodner R. . 1997 Cancer Res. 57: 808–811.

  • Kaye SB. . 1996 Ann. Oncol. 7: 9–13.

  • King BL, Carcangiu ML, Carter D, Kiechle M, Pfisterer J, Pfleiderer A and Kacinski BM. . 1995 Br. J. Cancer 72: 376–382.

  • Liu B, Nicolaides N, Markowitz S, Wilson JKV, Parsons RE, Jen J, Papadopoulos N, Peltomaki P, de la Chapelle A, Hamilton SR, Kinzler KW and Vogelstein B. . 1995 Nature Genetics 9: 48–54.

  • Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomaki P, de la Chapelle A, Hamilton SR, Vogelstein B and Kinzler KW. . 1996 Nature Med. 2: 169–174.

  • Lynch HT. . 1993 Gasteroenterology 104: 1535–1549.

  • Modrich P. . 1997 J Biol. Chem. 272: 24727–24730.

  • Neijt JP. . 1997 Textbook of Medical Oncology. Cavalli F, Hansen HH, Kaye SB, (eds). Martin Dunitz Ltd: London. pp.87–115.

    Google Scholar 

  • Nyce J. . 1989 Cancer Res. 49: 5829–5836.

  • Prolla TA, Baker SM, Harris AC, Tsao J, Yao X, Bronner E, Zheng B, Gordon M, Reneker J, Arnheim N, Shibata D, Bradley A and Liskay RM. . 1997 Nature Genet. 18: 276–279.

  • Reitmair AH, Redston M, Chun J, Chuang TCY, Bjerkness M, Cheng H, Hay K, Gallinger S, Bapat B and Mak TW. . 1996 Cancer Res. 56: 3842–3849.

  • Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, Moslein G, Baker SM, Liskay RM, Burgart LJ, Honchel R and Halling KC. . 1996 Cancer Res. 56: 4836–4840.

  • Zingg J and Jones PA. . 1997 Carcinogenesis 18: 869–882.

Download references

Acknowledgements

The authors would like to thank Prof SB Kaye for critical reading of the manuscript. This work is supported by the Cancer Research Campaign (UK).

Author information

Authors and Affiliations

  1. CRC Department of Medical Oncology, CRC Beatson Laboratories, Glasgow University, Switchback Road, G61 1BD, Glasgow, UK

    G Strathdee, M J MacKean, M Illand & R Brown

Authors
  1. G Strathdee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M J MacKean
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Illand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strathdee, G., MacKean, M., Illand, M. et al. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335–2341 (1999). https://doi.org/10.1038/sj.onc.1202540

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202540

Keywords

This article is cited by

Search

Advanced search

Quick links